Why Are Viridian Therapeutics Shares Moving Higher On Tuesday?

  • Viridian Therapeutics Inc VRDN has priced an underwritten public offering with approximately $85.0 million gross proceeds
  • Viridian will offer 6.18 million shares at $11.00 per share, and 23,126 shares of series B preferred stock at a public offering price of $733.37 per share, convertible into approximately 1.5 million shares.
  • The offer price is at a premium of around 3% on the last close price of $10.69 on Monday.
  • Underwriters have an option to purchase an additional 1.15 million shares. The offering will close by September 23.
  • Viridian will use the proceeds to develop VRDN-001 and VRDN-002 programs further and the preclinical development of its VRDN-004 and VRDN-005 programs.
  • The Company will submit IND filings for both VRDN-001 and VRDN-002 to the FDA in Q4 of 2021 
  • Initial VRDN-001 proof of concept clinical data in Thyroid Eye Disease is expected in Q2 of 2022.
  • VRDN-002 Phase 1 data in healthy volunteers is expected in mid-2022.
  • Jefferies, SVB Leerink, and Evercore ISI are acting as joint book-running managers for the offering.
  • The Company will present preclinical data on VRDN-001 and VRDN-002 at the American Thyroid Association Annual Meeting (September 30 to October 3).
  • Price Action: VRDN stock is up 17.40% at $12.55 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLong IdeasNewsHealth CareFinancingOfferingsMoversTrading IdeasGeneralBriefsEye DiseasesPreclinical Phasewhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!